UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 3.665

Sortiert nach

Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects

Journal of clinical pharmacology, 2016-05, Vol.56 (5), p.559-566

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors

Clinical cancer research, 2008-10, Vol.14 (20), p.6663-6673

2008

Link zum Volltext

Verfügbarkeit prüfen

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2017-09, Vol.12 (9), p.1357-1367

2017

Link zum Volltext

Verfügbarkeit prüfen

Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non–Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study

Journal of thoracic oncology, 2020-03, Vol.15 (3), p.392-403

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation

European journal of haematology, 2015-10, Vol.95 (4), p.316-324

2015

Link zum Volltext

Verfügbarkeit prüfen

Assessment of drug–drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer

Cancer chemotherapy and pharmacology, 2017-06, Vol.79 (6), p.1119-1128

2017

Link zum Volltext

Verfügbarkeit prüfen

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma

British journal of haematology, 2009-10, Vol.147 (1), p.97-101

2009

Link zum Volltext

Verfügbarkeit prüfen

Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors

Investigational new drugs, 2014-02, Vol.32 (1), p.135-144

2014

Link zum Volltext

Verfügbarkeit prüfen

A drug–drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2018, Vol.81 (1), p.73-80

2018

Link zum Volltext

Verfügbarkeit prüfen

A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258)

Cancer chemotherapy and pharmacology, 2015-04, Vol.75 (4), p.729-737

2015

Link zum Volltext

Verfügbarkeit prüfen

The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2014-10, Vol.74 (4), p.867-874

2014

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2016-11, Vol.78 (5), p.921-927

2016

Link zum Volltext

Verfügbarkeit prüfen

The deacetylase inhibitor LAQ824 induces notch signalling in haematopoietic progenitor cells

Leukemia research, 2011-01, Vol.35 (1), p.119-125

2011

Link zum Volltext

Verfügbarkeit prüfen

Vaccines and hurricanes don't mix

Paediatrics & child health, 2004-09, Vol.9 (7), p.453-456

2004

Link zum Volltext

Verfügbarkeit prüfen

An Educator's Guide to Assessing Threats in Student Writing: Social Media, Email and other Narrative

1st edition, 2021

Link zum Volltext

Verfügbarkeit prüfen

A randomized, crossover phase I study to assess the effects of formulation and meal consumption on the bioavailability of dovitinib (TKI258)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.2593-2593

2013

Link zum Volltext

Verfügbarkeit prüfen

Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.2502-2502

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 study assessing dovitinib (TKI258) on the pharmacokinetics of caffeine, diclofenac, omeprazole, and midazolam in patients with advanced solid tumors

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.2581-2581

2014

Link zum Volltext

Verfügbarkeit prüfen

A Phase 2, Multicenter, Nonrandomized, Open-Label Study of Dovitinib (TKI258) in Patients with Relapsed or Refractory Multiple Myeloma with or without t(4;14) Translocation

Blood, 2012-11, Vol.120 (21), p.4055-4055

2012

Link zum Volltext

Verfügbarkeit prüfen

Bicycle helmet use in Canada: The need for legislation to reduce the risk of head injury

Paediatrics & child health, 2013-11, Vol.18 (9), p.475-480

2013

Link zum Volltext

Verfügbarkeit prüfen

The Histone Deacetylase Inhibitor LAQ824 Maintains Normal Hematopoietic Progenitor cells (HPC) Associated with Induction of Notch Target Genes and Does Not Eliminate Leukemic HPC in Vitro

Blood, 2008-11, Vol.112 (11), p.1352-1352

2008

Link zum Volltext

Verfügbarkeit prüfen

Preventing choking and suffocation in children

Paediatrics & child health, 2012-02, Vol.17 (2), p.91-92

Cyr, Claude

2012

Link zum Volltext

Verfügbarkeit prüfen

Activity of Oral Panobinostat (LBH589) in Patients with Myelofibrosis

Blood, 2009-11, Vol.114 (22), p.2898-2898

2009

Link zum Volltext

Verfügbarkeit prüfen

Laboratory Tumor Lysis Syndrome Complicating LBH589 Therapy in a Patient with Acute Myeloid Leukemia

Blood, 2006-11, Vol.108 (11), p.4554-4554

2006

Link zum Volltext

Verfügbarkeit prüfen

Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies

Blood, 2008-11, Vol.112 (11), p.958-958

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 3.665

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(3.337)
Mit Volltextzugriff
(3.166)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(2.515)
Life Sciences & Biomedicine
(2.064)
Humans
(1.703)
Male
(970)
Female
(961)
Biological And Medical Sciences
(639)
Middle Aged
(562)
Medical Sciences
(523)
Animals
(513)
Adult
(508)
Aged
(469)
Physical Sciences
(345)
Surgery
(305)
Treatment Outcome
(279)
Cardiovascular System & Cardiology
(234)
Neurosciences & Neurology
(230)
Adolescent
(229)
Risk Factors
(214)
Mice
(211)
Child
(196)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects

Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non–Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study

Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation

Assessment of drug–drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma

Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors

A drug–drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors

A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258)

The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors

Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors

The deacetylase inhibitor LAQ824 induces notch signalling in haematopoietic progenitor cells

Vaccines and hurricanes don't mix

An Educator's Guide to Assessing Threats in Student Writing: Social Media, Email and other Narrative

A randomized, crossover phase I study to assess the effects of formulation and meal consumption on the bioavailability of dovitinib (TKI258)

Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC)

Phase 1 study assessing dovitinib (TKI258) on the pharmacokinetics of caffeine, diclofenac, omeprazole, and midazolam in patients with advanced solid tumors

A Phase 2, Multicenter, Nonrandomized, Open-Label Study of Dovitinib (TKI258) in Patients with Relapsed or Refractory Multiple Myeloma with or without t(4;14) Translocation

Bicycle helmet use in Canada: The need for legislation to reduce the risk of head injury

The Histone Deacetylase Inhibitor LAQ824 Maintains Normal Hematopoietic Progenitor cells (HPC) Associated with Induction of Notch Target Genes and Does Not Eliminate Leukemic HPC in Vitro

Preventing choking and suffocation in children

Activity of Oral Panobinostat (LBH589) in Patients with Myelofibrosis

Laboratory Tumor Lysis Syndrome Complicating LBH589 Therapy in a Patient with Acute Myeloid Leukemia

Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies

Suchergebnisse filtern